HALO - AlphaYou

HALO: Future Upside Will Rely On Expanding ENHANZE Drug Delivery Partnerships

BullishJul 24

Halozyme Therapeutics to report Q2 2026 results on August 6

NeutralJul 23

Halozyme to Report Second Quarter 2026 Financial and Operating Results

NeutralJul 23

Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model?

BullishJul 22

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Phathom Pharmaceuticals (PHAT) and Incyte (INCY)

Leans bullishJul 22

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Leans bullishJul 22

Halozyme’s Partnerships, Earnings Growth See Shares Near All-Time Highs

BullishJul 22

Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com

NeutralJul 21

Halozyme Therapeutics Inc